News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
263,874 Results
Type
Article (14075)
Company Profile (282)
Press Release (249517)
Section
Business (79443)
Career Advice (152)
Deals (13219)
Drug Delivery (34)
Drug Development (50388)
Employer Resources (31)
FDA (5701)
Job Trends (5121)
News (144274)
Policy (10027)
Tag
Academia (901)
Alliances (21603)
Alzheimer's disease (785)
Antibody-drug conjugate (ADC) (72)
Approvals (5690)
Artificial intelligence (91)
Bankruptcy (101)
Best Places to Work (4559)
Biotechnology (232)
Breast cancer (126)
Cancer (1062)
Cardiovascular disease (85)
Career advice (132)
CAR-T (88)
Cell therapy (252)
Clinical research (40478)
Collaboration (415)
Compensation (174)
COVID-19 (1020)
C-suite (110)
Cystic fibrosis (74)
Data (1091)
Diabetes (101)
Diagnostics (1256)
Earnings (29121)
Events (47566)
Executive appointments (338)
FDA (6167)
Funding (391)
Gene editing (74)
Gene therapy (189)
GLP-1 (336)
Government (1072)
Healthcare (6565)
Infectious disease (1069)
Inflammatory bowel disease (100)
IPO (7242)
Job creations (859)
Job search strategy (127)
Layoffs (195)
Legal (1384)
Lung cancer (159)
Manufacturing (99)
Medical device (2569)
Medtech (2570)
Mergers & acquisitions (6197)
Metabolic disorders (305)
Neuroscience (1086)
NextGen: Class of 2025 (2014)
Non-profit (853)
Northern California (1275)
Obesity (164)
Opinion (95)
Parkinson's disease (88)
Patents (75)
People (25304)
Phase I (14289)
Phase II (18833)
Phase III (11899)
Pipeline (475)
Postmarket research (852)
Preclinical (5989)
Radiopharmaceuticals (209)
Rare diseases (238)
Real estate (1411)
Regulatory (8392)
Research institute (932)
Series A (75)
Southern California (1145)
Startups (1968)
United States (10138)
Vaccines (187)
Weight loss (94)
Date
Today (63)
Last 7 days (342)
Last 30 days (1455)
Last 365 days (20471)
2025 (2031)
2024 (20552)
2023 (22414)
2022 (26822)
2021 (27806)
2020 (23359)
2019 (16228)
2018 (11741)
2017 (13747)
2016 (11840)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7429)
Location
Africa (148)
Asia (17062)
Australia (2887)
California (2918)
Canada (927)
China (261)
Colorado (112)
Connecticut (120)
Delaware (68)
Europe (36701)
Florida (333)
Georgia (87)
Illinois (187)
Indiana (70)
Maryland (382)
Massachusetts (2314)
Minnesota (115)
New Jersey (727)
New York (802)
North Carolina (462)
Northern California (1275)
Ohio (95)
Pennsylvania (551)
South America (207)
Southern California (1145)
Texas (325)
Washington State (282)
263,874 Results for "tempest therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - February 7, 2025
February 9, 2025
·
1 min read
Press Releases
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
February 10, 2025
·
7 min read
Biotech Bay
Tempest to Participate in Upcoming Investor Conferences - May 21, 2024
Tempest Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, announced that management will participate in the following upcoming investor conferences.
May 21, 2024
·
1 min read
Press Releases
Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 25, 2024
·
1 min read
Drug Development
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
Tempest Therapeutics, Inc. announced new positive data from the ongoing global randomized Phase 1b/2 clinical study in which amezalpat2, Tempest’s PPAR⍺ antagonist, delivered a six-month improvement in median overall survival advantage when combined with atezolizumab and bevacizumab in a comparison to atezolizumab and bevacizumab alone in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma.
June 20, 2024
·
9 min read
Press Releases
Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)
January 6, 2025
·
7 min read
Business
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
Tempest Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, reported financial results for the quarter ended March 31, 2024, and provided a corporate update.
May 9, 2024
·
8 min read
Press Releases
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - December 6, 2024
December 9, 2024
·
1 min read
Press Releases
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
November 13, 2024
·
9 min read
Press Releases
Tempest Extends Limited Duration Stockholder Rights Plan
October 11, 2024
·
6 min read
1 of 26,388
Next
